New Treatment Addressing the Pathogenesis of Psoriasis
Psoriasis is an immune cell-mediated inflammatory skin disease. The interleukin (IL)23/IL17 axis plays an important role in the development of psoriasis. The effectiveness of biologic treatments such as tumor necrosis factor (TNF)α inhibitors (infliximab, adalimumab, certolizumab pegol), IL23 inhibi...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/20/7488 |
id |
doaj-94cdf9c402da400eb5ed745fc566ea94 |
---|---|
record_format |
Article |
spelling |
doaj-94cdf9c402da400eb5ed745fc566ea942020-11-25T03:40:32ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-10-01217488748810.3390/ijms21207488New Treatment Addressing the Pathogenesis of PsoriasisMichio Tokuyama0Tomotaka Mabuchi1Department of Dermatology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, JapanDepartment of Dermatology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, JapanPsoriasis is an immune cell-mediated inflammatory skin disease. The interleukin (IL)23/IL17 axis plays an important role in the development of psoriasis. The effectiveness of biologic treatments such as tumor necrosis factor (TNF)α inhibitors (infliximab, adalimumab, certolizumab pegol), IL23 inhibitors (ustekinumab, guselkumab, tildrakizumab, risankizumab), and IL17 inhibitors (secukinumab, ixekizumab, brodalumab) have verified these findings. Immune-related cells such as dendritic cells (DCs) and macrophages, in addition to Toll-like receptors and cytokines such as interferon (IFN)α, TNFα, IFNɤ, IL12, IL22, IL23, and IL17, are related to the pathogenesis of psoriasis. Here, we first review new insights regarding the pathogenesis of psoriasis, as it relates to DCs, Langerhans cells, macrophages, the signal transducer and activator of transcription 3 pathway, and aryl hydrocarbon receptor in cutaneous vascular endothelial cells. Based on these findings, we summarize currently available oral treatments and biologics. Furthermore, we describe a new treatment option including Janus kinase inhibitor, tyrosine kinase 2 inhibitor, modulator of sphingosine 1-phosphate receptor 1, and Rho-associated kinase 2 inhibitor.https://www.mdpi.com/1422-0067/21/20/7488psoriasisnew treatmentpathogenesisdendritic cellsJanus kinase inhibitorsphingosine 1-phosphate receptor 1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michio Tokuyama Tomotaka Mabuchi |
spellingShingle |
Michio Tokuyama Tomotaka Mabuchi New Treatment Addressing the Pathogenesis of Psoriasis International Journal of Molecular Sciences psoriasis new treatment pathogenesis dendritic cells Janus kinase inhibitor sphingosine 1-phosphate receptor 1 |
author_facet |
Michio Tokuyama Tomotaka Mabuchi |
author_sort |
Michio Tokuyama |
title |
New Treatment Addressing the Pathogenesis of Psoriasis |
title_short |
New Treatment Addressing the Pathogenesis of Psoriasis |
title_full |
New Treatment Addressing the Pathogenesis of Psoriasis |
title_fullStr |
New Treatment Addressing the Pathogenesis of Psoriasis |
title_full_unstemmed |
New Treatment Addressing the Pathogenesis of Psoriasis |
title_sort |
new treatment addressing the pathogenesis of psoriasis |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2020-10-01 |
description |
Psoriasis is an immune cell-mediated inflammatory skin disease. The interleukin (IL)23/IL17 axis plays an important role in the development of psoriasis. The effectiveness of biologic treatments such as tumor necrosis factor (TNF)α inhibitors (infliximab, adalimumab, certolizumab pegol), IL23 inhibitors (ustekinumab, guselkumab, tildrakizumab, risankizumab), and IL17 inhibitors (secukinumab, ixekizumab, brodalumab) have verified these findings. Immune-related cells such as dendritic cells (DCs) and macrophages, in addition to Toll-like receptors and cytokines such as interferon (IFN)α, TNFα, IFNɤ, IL12, IL22, IL23, and IL17, are related to the pathogenesis of psoriasis. Here, we first review new insights regarding the pathogenesis of psoriasis, as it relates to DCs, Langerhans cells, macrophages, the signal transducer and activator of transcription 3 pathway, and aryl hydrocarbon receptor in cutaneous vascular endothelial cells. Based on these findings, we summarize currently available oral treatments and biologics. Furthermore, we describe a new treatment option including Janus kinase inhibitor, tyrosine kinase 2 inhibitor, modulator of sphingosine 1-phosphate receptor 1, and Rho-associated kinase 2 inhibitor. |
topic |
psoriasis new treatment pathogenesis dendritic cells Janus kinase inhibitor sphingosine 1-phosphate receptor 1 |
url |
https://www.mdpi.com/1422-0067/21/20/7488 |
work_keys_str_mv |
AT michiotokuyama newtreatmentaddressingthepathogenesisofpsoriasis AT tomotakamabuchi newtreatmentaddressingthepathogenesisofpsoriasis |
_version_ |
1724534153131589632 |